Skip to main content
Acticor Biotech logo

Acticor Biotech — Investor Relations & Filings

Ticker · ALACT ISIN · FR0012519668 LEI · 969500K433EK1G89EV95 PA Manufacturing
Open in API
Filings indexed 200 across all filing types
Latest filing 2024-07-09 Report Publication Anno…
Country FR France
Listing PA ALACT

About Acticor Biotech

https://www.acticor-biotech.com

Acticor Biotech is a clinical-stage biopharmaceutical company that originated as a spin-off from the French National Institute of Health and Medical Research (INSERM). The company is dedicated to developing innovative treatments for thrombotic diseases, with a primary focus on the acute phase of ischemic stroke. Its lead drug candidate, glenzocimab, is a humanized monoclonal antibody fragment designed to target platelet glycoprotein VI (GPVI), a key receptor involved in thrombosis. The therapeutic approach aims to provide an effective anti-thrombotic effect to safely manage stroke patients without increasing the risk of bleeding, a significant complication associated with existing treatments.

Recent filings

Filing Released Lang Actions
Inside Information / News release on accounts, results
Report Publication Announcement Classification · 95% confidence The document is a press release from Acticor Biotech announcing its 2023 annual results. While it contains summary financial tables (income statement and balance sheet), it explicitly states that the full 'Universal Registration Document' (which includes the annual financial report) has been filed separately with the AMF and is available on their website. According to the 'Menu vs Meal' rule, this document is an announcement of the report rather than the full annual report itself. Therefore, it is classified as a Report Publication Announcement (RPA). FY 2023
2024-07-09 English
Informations privilégiées / Communiqué sur comptes, résultats
Earnings Release Classification · 95% confidence The document is a press release from Acticor Biotech announcing its 2023 annual financial results. It provides key financial highlights (R&D costs, net loss, cash position) and includes summary tables of the income statement and balance sheet. While it mentions the availability of the 'Document d'Enregistrement Universel' (Universal Registration Document), the document itself serves as the initial public announcement of the annual financial performance, which fits the definition of an Earnings Release (ER). FY 2023
2024-07-09 French
Total number of voting rights and capital / Information on the total number of voting rights and the number of shares making up the capital
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "Disclosure of the total number of voting rights and shares as of May 31, 2024" and is explicitly stated to be disclosed pursuant to French Commercial Code and AMF regulations. It provides a table detailing the number of shares and voting rights as of a specific date (May 31, 2024), issued on July 5, 2024. This type of mandatory disclosure regarding the total share capital and voting power is a specific regulatory filing requirement, often related to capital structure updates or general corporate governance disclosures. It is not an Annual Report (10-K), an Earnings Release (ER), or a Dividend Notice (DIV). Since it deals specifically with the total number of shares and voting rights, it most closely aligns with a notification about the capital structure or a general regulatory update. Given the options, it is a specific regulatory disclosure that doesn't fit perfectly into the financial report categories (10-K, IR, ER). However, it is a formal disclosure of share capital structure information. While 'SHA' (Share Issue/Capital Change) might seem relevant, this is a periodic disclosure of the *current* total, not an announcement of a *change* or *issue*. It is a formal regulatory communication. Since it is a formal, required disclosure that doesn't fit the specific financial report types, the best fit among the provided options is 'RNS' (Regulatory Filings) as a general regulatory announcement, or potentially 'SHA' if interpreted broadly as capital structure reporting. Given the context of French regulatory filings, these periodic share capital disclosures are often categorized broadly. Since it is a formal, required disclosure of share capital status, and not a general press release about an event, 'RNS' is the most appropriate fallback for a specific regulatory notification that lacks a more precise category like 'DEF 14A' or 'DVA'. However, upon re-evaluation, this specific type of filing (total voting rights disclosure) is often grouped with capital structure announcements. Since 'SHA' is defined as 'Share Issue/Capital Change', and this is a report on the current state of capital/voting rights, it is a strong candidate. Given the strict definitions, and the fact that it is a mandatory disclosure about the composition of the share capital, I will classify it as a general Regulatory Filing (RNS) as it is a routine compliance disclosure rather than a specific event like an issue or buyback.
2024-07-05 English
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social au 31 mai 2024" (Monthly information relating to the total number of voting rights and shares comprising the share capital as of May 31, 2024). It explicitly references Article 223-16 of the AMF General Regulation (Autorité des Marchés Financiers) and provides a table detailing the total number of shares and theoretical/real voting rights as of a specific date (May 31, 2024). This type of mandatory periodic disclosure regarding the share capital structure and voting rights is a specific regulatory filing requirement in France, often falling under general regulatory announcements or specific capital structure updates. Given the options, this is a mandatory regulatory disclosure concerning the capital structure and voting rights, which is best categorized as a general Regulatory Filing (RNS) or potentially related to Share Issue/Capital Change (SHA) if it were a change, but since it's a periodic statement of the current count, RNS is the most appropriate general regulatory bucket, or if a more specific category existed for voting rights reports, that would be used. However, looking at the definitions, none perfectly match a 'Monthly Voting Rights Statement'. It is a regulatory announcement, not an earnings release (ER), annual report (10-K), or interim report (IR). It is a specific regulatory disclosure, making RNS the best fit as a general regulatory filing.
2024-07-05 French
Inside Information / Other news releases
Earnings Release Classification · 95% confidence The document is a press release dated June 3, 2024, providing an update on the clinical development plan for the drug glenzocimab, specifically detailing results from the ACTISAVE study and outlining future/ongoing studies (GREEN, GALICE, LIBERATE). It discusses clinical trial outcomes, patient subpopulations, and future strategic direction (seeking partners). This content aligns best with an Earnings Release (ER) which often includes operational and clinical updates alongside financial highlights, or potentially an Investor Presentation (IP) if it were structured as slides, but given the format and focus on recent results/updates, it functions as a key corporate announcement regarding performance and pipeline. Since it is an update on clinical progress following a recent study presentation (ESOC in May 2024) and outlines future plans, it is most accurately classified as an Earnings Release (ER) or a general corporate update. Given the focus on clinical trial results and strategic updates rather than just preliminary financial figures, and lacking the comprehensive nature of a 10-K or IR, ER is the closest fit for a major periodic update announcement. FY 2024
2024-06-03 English
Informations privilégiées / Autres communiqués
Earnings Release Classification · 95% confidence The document is a press release dated June 3, 2024, providing an update on the clinical development plan for the drug glenzocimab, specifically discussing results from the ACTISAVE Phase 2/3 study and outlining ongoing/planned studies (GREEN, GALICE, LIBERATE). It details scientific findings, patient subpopulations, and future strategy, including seeking partners. This content structure—a corporate announcement summarizing recent scientific/clinical progress and future pipeline updates—is characteristic of an Earnings Release (ER) or a general corporate update. Since it is not a full financial report (10-K/IR) or a transcript (CT), and it focuses on operational/clinical progress rather than just dividend/share changes, the best fit among the provided options is the Earnings Release (ER), as these often contain operational highlights and management commentary following a significant event (like the ESOC presentation mentioned). It is not a Report Publication Announcement (RPA) because it contains substantial analysis and forward-looking statements, not just a notification that a report is available. FY 2024
2024-06-03 French

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.